George K. Papadopoulos

George K. Papadopoulos

Auto-generated profile, based on publicly available information

George K. Papadopoulos

Laboratory of Biophysics, Biochemistry, Biomaterials and Bioprocessing, Faculty of Agricultural Technology, Technological Educational Institute (TEI) of Epirus, Arta, Greece

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2007 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
GBGeorge P. Bondinas
George P. Bondinas
AMAntonis K. Moustakas
Antonis K. Moustakas
GPGeorge K. Papadopoulos
George K. Papadopoulos

1 September 2009 in Journal of Molecular Catalysis B: Enzymatic
Verified
Journal Article
Closed access
Ioannis PavlidisIoannis Pavlidis
Ioannis Pavlidis
Dimitrios GournisDimitrios Gournis
Dimitrios Gournis
GPGeorge K. Papadopoulos
George K. Papadopoulos
Haralambos StamatisHaralambos Stamatis
Haralambos Stamatis

7 June 2010 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
Eddie A. JamesEddie A. James
Eddie A. James
AMAntonis K. Moustakas
Antonis K. Moustakas
JBJohn Bui
John Bui
GPGeorge K. Papadopoulos
George K. Papadopoulos
GBGeorge Bondinas
George Bondinas
WKWilliam W. Kwok
William W. Kwok
Objective: HLA–DRB1*1001 (DR1001) is a shared epitope allele associated with rheumatoid arthritis (RA). The present study was undertaken to assess the capacity of DR1001 to accommodate citrulline in its binding pockets and to identify citrullinated T cell epitopes derived from joint‐associated proteins.Methods: The binding of peptide derivatives containing citrulline, arginine, and other amino acid substitutions was measured. A prediction algorithm was developed to identify arginine‐containing sequences from joint‐associated proteins that preferentially bind to DR1001 upon citrullination. Unmodified and citrullinated versions of these sequences were synthesized and were utilized to stimulate CD4+ T cells from healthy subjects and RA patients. Responses were measured by class II major histocompatibility complex tetramer staining and confirmed by isolating CD4+ T cell clones.Results: DR1001 accepted citrulline, but not arginine, in 3 of its anchoring pockets. The prediction algorithm identified sequences that preferentially bound to DR1001 with arginine replaced by citrulline. Three of these sequences elicited CD4+ T cell responses. T cell clones specific for these sequences proliferated only in response to citrullinated peptides.Conclusion: Conversion of arginine to citrulline generates “altered‐self” peptides that can be bound and presented by DR1001. Responses to these peptides implicate the corresponding proteins (fibrinogen α, fibrinogen β, and cartilage intermediate‐layer protein) as relevant antigens. The finding of preferential responses to citrullinated sequences suggests that altered peptide binding affinity due to this posttranslational modification may be an important factor in the initiation or progression of RA. As such, measuring responsiveness to these peptides may be useful for immunologic monitoring.

1 March 1989 in Clinical Immunology and Immunopathology
Verified
Journal Article
Closed access
MMMenelaus N. Manoussakis
Menelaus N. Manoussakis
GPGeorge K. Papadopoulos
George K. Papadopoulos
ADAlexandros A. Drosos
Alexandros A. Drosos
HMHaralampos M. Moutsopoulos
Haralampos M. Moutsopoulos

1 August 1999 in Clinical Immunology
Verified
Journal Article
Closed access
PVP.V. Voulgari
P.V. Voulgari
GKG. Kolios
G. Kolios
GPG.K. Papadopoulos
G.K. Papadopoulos
AKA. Katsaraki
A. Katsaraki
KSK. Seferiadis
K. Seferiadis
ADA.A. Drosos
A.A. Drosos

1 March 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MLMenno van Lummel
Menno van Lummel
PVPeter A. van Veelen
Peter A. van Veelen
AZArnaud Zaldumbide
Arnaud Zaldumbide
ARArnoud de Ru
Arnoud de Ru
GJGeorge M.C. Janssen
George M.C. Janssen
FKFrits Koning
Frits Koning
HLA-DQ2 and HLA-DQ8 are strongly predisposing haplotypes for type 1 diabetes (T1D). Yet HLA-DQ2/8 heterozygous individuals have a synergistically increased risk compared with HLA-DQ2 or HLA-DQ8 homozygote subjects that may result from the presence of a transdimer formed between the α-chain of HLA-DQ2 (DQA1*05:01) and the β-chain of HLA-DQ8 (DQB1*03:02). We generated cells exclusively expressing this transdimer (HLA-DQ8trans), characterized its peptide binding repertoire, and defined a unique transdimer-specific peptide binding motif that was found to be distinct from those of HLA-DQ2 and HLA-DQ8. This motif predicts an array of peptides of islet autoantigens as candidate T cell epitopes, many of which selectively bind to the HLA transdimer, whereas others bind to both HLA-DQ8 and transdimer with similar affinity. Our findings provide a molecular basis for the association between HLA-DQ transdimers and T1D and set the stage for rational testing of potential diabetogenic peptide epitopes.